A Stock Analysis: Buy, Sell, or Hold?
A - Agilent Technologies Inc.
$113.26
0.52 (0.46%)
▲
5d:
-4.54%
30d:
-5.44%
90d:
-9.3%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 27, 2026
12d
Smart Money Accumulation
A is down 7.6% this week, but smart money is accumulating calls. Top strike: $130 2026-06-18 with 562 OI. Call ratio: 71% View Scanner →
Strength: 5.9/10
Get Alerted When A Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: A trading at deep discount. Market pricing in -4.6% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: A trading at deep discount. Market pricing in -4.6% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$182.95
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$113.59
0.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: A is currently trading at $113.26, which is considered oversold relative to its 30-day fair value range of $113.32 to $119.39. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.1) compared to its historical average (19.7). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, A is in a strong downtrend. The price is currently testing key support at $111.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $160.69 (+42.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, A is in a strong downtrend. The price is currently testing key support at $111.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $160.69 (+42.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$113.32 -
$119.39
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.5% below Wall St target ($160.69)
Trading Range Analysis
30-Day Trading Range
$113.32 -
$119.39
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$111.09
Resistance Level
$120.28
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.13
Wall Street Target
$160.69
(+42.5%)
Revenue Growth (YoY)
7.0%
Earnings Growth (YoY)
-3.6%
Profit Margin
18.3%
Valuation Discount vs History
-4.6% cheaper
PE vs Historical
17.1 vs 19.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.6%
(market-implied from PE analysis)
1-Year Target
$107.55
(-5%)
2-Year Target
$102.61
(-9%)
3-Year Target
$97.89
(-13%)
3-Yr Target (if PE normalizes)
(PE: 17→20)
$112.58
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 10.3%)
$194.45
(+73%)
Base:
(SPY PE: 17.1, Growth: 10.3%)
$151.12
(+34%)
Bear:
(PE: 14.6, Growth: 10.3%)
$128.45
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 24.97 | Current EPS (TTM): $4.53
Bull Case
$180.82
(+60%)
Analyst growth 45.3%, PE expands to 27.5
Base Case
$164.39
(+46%)
Market implied 45.3%, PE stable at 25.0
Bear Case
$76.93
(-32%)
Severe decline -20.0%, PE contracts to 21.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.1 to 19.7
Stabilization Target:
$129.67
(+15.0%)
PE Expansion Potential:
+15.0%
Share & Embed Analysis
Last updated: May 14, 2026 4:47 PM ET
Data refreshes hourly during market hours. Next update: 5:47 PM
Data refreshes hourly during market hours. Next update: 5:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is A showing a specific setup today?
Insider Activity (6 Months)
1
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Ro Khanna
BUY
2026-03-10
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$620 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$250 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$130 | 59 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 58 HOLD |
Advanced A Option Strategies
Professional options setups generated by AI based on today's A price and gamma walls.
